Atea Pharmaceuticals, Inc. (AVIR)

7.55 +0.21 (+2.93%) At close: 04:00PM EDT

Atea Pharmaceuticals, Inc.

125 Summer Street
Boston, MA 02110
United States
857 284 8891
https://ateapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 64

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jean-Pierre Sommadossi Ph.D.	Founder, Chairman, CEO & Pres	981.5k	N/A	1956
Ms. Andrea J. Corcoran J.D.	CFO, Exec. VP of Legal & Sec.	653.39k	N/A	1962
Mr. John F. Vavricka	Chief Commercial Officer	528.52k	N/A	1964
Dr. Janet M.J. Hammond M.D., Ph.D.	Chief Devel. Officer	723.59k	N/A	1960
Dr. Maria Arantxa Horga M.D.	Chief Medical Officer	605.98k	N/A	1968
Mr. Wayne Foster CPA, CPA	Exec. VP of Fin. & Chief Accounting Officer	N/A	N/A	1969
Ms. Jonae R. Barnes	Sr. VP of Investor Relations & Corp. Communications	N/A	N/A	N/A
Mr. Ariyapadi N. Krishnaraj	VP of Marketing	N/A	N/A	N/A
Mr. Adel Moussa Ph.D.	Exec. VP of Chemistry	N/A	N/A	N/A
Mr. Xiao-Jian Zhou Ph.D.	Exec. VP of Early Stage Devel.	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Corporate governance

Atea Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2022 is 9. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.